Publication:
The in vitro activity of danofloxacin plus ceftiofur combination: Implications for antimicrobial efficacy and resistance prevention

dc.contributor.buuauthorCengiz, Murat
dc.contributor.buuauthorCENGİZ, MURAT
dc.contributor.buuauthorŞahintürk, Pınar
dc.contributor.buuauthorHepbostancı, Gülce
dc.contributor.buuauthorAkalın, Halis
dc.contributor.buuauthorAKALIN, EMİN HALİS
dc.contributor.buuauthorSonal, Songül
dc.contributor.buuauthorSONAL, SONGÜL
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentFarmakoloji Ana Bilim Dalı
dc.contributor.orcid0000-0001-7530-1279
dc.contributor.researcheridABE-5935-2020
dc.contributor.researcheridAAU-8952-2020
dc.date.accessioned2024-10-04T12:39:29Z
dc.date.available2024-10-04T12:39:29Z
dc.date.issued2022-03-01
dc.description.abstractDue to the high prevalence of multi-drug resistant bacteria, combination therapy is an efficient choice for treatment of infections caused by highly resistant strains. In this study, the efficacy of ceftiofur plus danofloxacin combination was investigated against resistant Escherichia coli. The interaction between the two drugs was determined by checkerboard tests and time-kill assays. The combination was defined as bactericidal or bacteriostatic based on the minimum bactericidal concentration test results. Mutant prevention concentration test was used to evaluate the resistance tendency suppression potential of the combination. The combination had a synergistic effect against 83.00% of the isolates as verified by the checkerboard and time-kill assays. The combination was defined as bactericidal against all E. coli strains, since minimum bactericidal concentration: minimum inhibitory concentration ratios were below four thresholds and also markedly reduced mutant prevention concentration values of ceftiofur up to 4000-fold compared to its single use. Ceftiofur plus danofloxacin combination inhibited growth of E. coli strains which were resistant to ceftiofur or newer generation of fluoroquinolones. Our results suggest that ceftiofur plus danofloxacin combination has a bactericidal characteristic and can be an important alternative for the treatment of infections caused by resistant E. coli.
dc.identifier.doi10.30466/vrf.2020.113272.2696
dc.identifier.endpage153
dc.identifier.issn2008-8140
dc.identifier.issue2
dc.identifier.startpage149
dc.identifier.urihttps://doi.org/10.30466/vrf.2020.113272.2696
dc.identifier.urihttps://hdl.handle.net/11452/45898
dc.identifier.volume13
dc.identifier.wos000814095500001
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherUrmia Univ
dc.relation.journalVeterinary Research Forum
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.relation.tubitakTOVAG-214O316
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectMutant prevention
dc.subjectBeta-lactams
dc.subjectPseudomonas-aeruginosa
dc.subjectTime-kill
dc.subjectCiprofloxacin
dc.subjectSynergy
dc.subjectFluoroquinolones
dc.subjectLevofloxacin
dc.subjectSelection
dc.subjectCheckerboard
dc.subjectCeftiofur
dc.subjectDanofloxacin
dc.subjectEscherichia coli
dc.subjectIn vitro activity
dc.subjectMulti-drug resistance
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectVeterinary sciences
dc.subjectZoology
dc.titleThe in vitro activity of danofloxacin plus ceftiofur combination: Implications for antimicrobial efficacy and resistance prevention
dc.typeArticle
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Farmakoloji Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Klinik Mikrobiyoloji Ana Bilim Dalı
relation.isAuthorOfPublicationa96ca6a7-d471-4c71-a72f-1648cc98f911
relation.isAuthorOfPublication4fb46529-3295-4383-97b1-7c494ff32c24
relation.isAuthorOfPublicationf282550e-59f0-4426-b710-630a20d24459
relation.isAuthorOfPublication.latestForDiscoverya96ca6a7-d471-4c71-a72f-1648cc98f911

Files

Collections